How VYNDAMAX WorksTafamidis is a disease-modifying therapy that inhibits cardiac amyloidosis by selectively stabilizing TTR1-5 Tafamidis specifically targets TTR and fortifies the TTR tetramer to help preserve its natural function5-9
- The approved dose of tafamidis provides near-maximum stabilization10*†
- Stabilized TTR can continue to circulate naturally to perform critical biologic functions1-4
- Biomarkers associated with heart failure (NT-proBNP and Troponin I) favored VYNDAQEL over placebo11
Next: Safety profile ContinueLoadingRelationship between TTR occupancy by tafamidis and TTR stabilization was evaluated analyzing data from ATTR-ACT using models of TTR concentrations in human plasma.6The degree the tetramer dissociation rate is decreased in human plasma following the approved dose of tafamidis.6ATTR-ACT=Transthyretin Amyloidosis Cardiomyopathy Clinical Trial; NT-proBNP=N-terminal pro-B-type natriuretic peptide; TTR=transthyretin.
References: Maurer MS, Hanna M, Grogan M, et al; THAOS Investigators. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161-172. Rubin J, Alvarez J, Teruya S, et al. Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloidosis: can we identify affected patients earlier? Amyloid. 2017;24(4):224-228. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2—evidence base and standardized methods of imaging. Circ Cardiovasc Imaging. 2021;14(7):e000029. Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799-2806. Data on file. Pfizer Inc., New York, NY. Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86(9):1036-1043. Judge DP, Heitner SB, Falk RH, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2019;74(3):285-295. Coelho T, Merlini G, Bulawa CE, et al. Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther. 2016;5(1):1-25. Monteiro C, Martins da Silva A, Ferreira N, et al. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients. Amyloid. 2018;25(2):120-128. Tess DA, Maurer TS, Li Z, et al. Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy. Amyloid. 2023;30(2):208-219. Vyndaqel and Vyndamax [prescribing information]. New York, NY: Pfizer Inc; 2023.